Transient prehypertensive treatment in spontaneously hypertensive rats: A comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection

International Journal of Molecular Medicine

Volumn 30, Issue 6, 2012, Pages 1376-1386

  Peng, Feng ^a   Lin, Jinxiu ^a   Lin, Liming ^a   Tang, Hong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Amlodipine; Blood pressure; Losartan; Prehypertensive treatment; Renin angiotensin system; Spontaneously hypertensive rats

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; LOSARTAN;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; COLLAGEN VOLUME FRACTION; CONTROLLED STUDY; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART PROTECTION; HYPERTENSION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WESTERN BLOTTING;

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOTONIC AGENTS; COLLAGEN; GENE EXPRESSION REGULATION; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; LOSARTAN; MALE; NATRIURETIC PEPTIDE, BRAIN; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; STROKE VOLUME; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84869444385     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1153     Document Type: Article

References (33)

1. Vasan RS, Larson MG, Leip EP, Kannel WB and Levy D: Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 358: 1682-1686, 2001. (Pubitemid 33124327)
2. Hsia J, Margolis KL, Eaton CB, et al: Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 115: 855-860, 2007. (Pubitemid 46294726)
3. Knecht S, Wersching H, Lohmann H, et al: High-normal blood pressure is associated with poor cognitive performance. Hypertension 51: 663-668, 2008. (Pubitemid 351301518)
4. Mullican DR, Lorenzo C and Haffner SM: Is prehypertension a risk factor for the development of type 2 diabetes? Diabetes Care 32: 1870-1872, 2009.
5. Ninomiya T, Kubo M, Doi Y, et al: Prehypertension increases the risk for renal arteriosclerosis in autopsies: the Hisayama Study. J Am Soc Nephrol 18: 2135-2142, 2007. (Pubitemid 47041079)
6. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572, 2003. (Pubitemid 37430158)
7. Julius S, Nesbitt SD, Egan BM, et al: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354: 1685-1697, 2006.
8. Luders S, Schrader J, Berger J, et al: The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26: 1487-1496, 2008.
9. Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F and Lever AF: Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 16: 603-614, 1990.
10. Baumann M, Janssen BJ, Hermans JJ, et al: Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 25: 207-215, 2007. (Pubitemid 44885683)
11. Baumann M, Hermans JJ, Janssen BJ, et al: Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. J Hypertens 25: 2504-2511, 2007. (Pubitemid 350060390)
12. Tomassoni D, Sabbatini M and Amenta F: Effect of different dihydropyridine-type Ca2+ antagonists on left ventricle hypertrophy and coronary changes in spontaneously hypertensive rats. J Cardiovasc Pharmacol 41: 544-552, 2003. (Pubitemid 36373791)
13. Watanabe M, Kawaguchi H, Onozuka H, et al: Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts. J Cardiovasc Pharmacol 32: 248-259, 1998. (Pubitemid 28350645)
14. Widdop RE and Li XC: A simple versatile method for measuring tail cuff systolic blood pressure in conscious rats. Clin Sci (Lond) 93: 191-194, 1997. (Pubitemid 27387056)
15. Lang RM, Bierig M, Devereux RB, et al: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463, 2005. (Pubitemid 41821197)
16. Floege J, Hackmann B, Kliem V, et al: Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int 51: 230-243, 1997. (Pubitemid 27064542)
17. Xu Y, Kumar D, Dyck JR, et al: AT(1) and AT(2) receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol Heart Circ Physiol 282: H1206-H1215, 2002. (Pubitemid 34657253)
18. Christensen KL, Jespersen LT and Mulvany MJ: Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertens 7: 83-90, 1989. (Pubitemid 19073982)
19. Ishiguro K, Sasamura H, Sakamaki Y, Itoh H and Saruta T: Developmental activity of the renin-angiotensin system during the 'critical period' modulates later L-NAME-induced hypertension and renal injury. Hypertens Res 30: 63-75, 2007.
20. Nakaya H, Sasamura H, Mifune M, et al: Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 91: 710-718, 2002. (Pubitemid 34914076)
21. Sasamura H, Hayashi K, Ishiguro K, Nakaya H, Saruta T and Itoh H: Prevention and regression of hypertension: role of renal microvascular protection. Hypertens Res 32: 658-664, 2009.
22. Keaton AK, White CR and Berecek KH: Captopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive rat. Clin Exp Hypertens 20: 847-866, 1998. (Pubitemid 28487519)
23. Zhang L, Edwards DG and Berecek KH: Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Clin Exp Hypertens 18: 201-226, 1996. (Pubitemid 26109954)
24. Wu JN and Berecek KH: Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 22: 139-146, 1993.
25. Baumann M, Janssen BJ, Rob Hermans JJ, Bartholome R, Smits JF and Struijker Boudier HA: Renal medullary effects of transient prehypertensive treatment in young spontaneously hypertensive rats. Acta Physiol (Oxf) 196: 231-237, 2009.
26. Sevilla MA, Voces F, Carron R, et al: Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. Life Sci 75: 881-891, 2004. (Pubitemid 38737424)
27. Takemori K, Ishida H and Ito H: Continuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive rats. Life Sci 77: 2233-2245, 2005. (Pubitemid 41169959)
28. Bader M: Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol 34: 1455-1462, 2002.
29. Mizuno K, Tani M, Hashimoto S, et al: Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 51: 367-374, 1992.
30. Adams MA, Bobik A and Korner PI: Differential development of vascular and cardiac hypertrophy in genetic hypertension. Relation to sympathetic function. Hypertension 14: 191-202, 1989. (Pubitemid 19205174)
31. Burges R and Moisey D: Unique pharmacologic properties of amlodipine. Am J Cardiol 73: 2A-9A, 1994. (Pubitemid 24075268)
32. Naito T, Ma LJ, Yang H, et al: Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol 298: F683-F691, 2010.
33. Skov K, Eiskjaer H, Hansen HE, Madsen JK, Kvist S and Mulvany MJ: Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 50: 89-95, 2007. (Pubitemid 46986015)